Information Provided By: 
Fly News Breaks for January 20, 2020
AMRN
Jan 20, 2020 | 16:13 EDT
Jefferies analyst Michael Yee maintains a Buy rating, with a $30 price target, on Amarin's shares as he believes the company remains in a "good position" to protect its patents on "infringement" and "obviousness." The analyst does not believe the generics have made a strong case or met the burden for proving they do not infringe, and obviousness.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
